Krispy Kreme, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 15, 2025 to Discuss Your Rights
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Krispy Kreme, Inc. investors who were adversely affected by alleged securities fraud between February 25, 2025 and May 7, 2025. Follow the link below to get more information and be contacted by a member of our team:
https://zlk.com/pslra-1/krispy-kreme-inc-lawsuit-submission-form?prid=154155&wire=56
DNUT investors may also contact Joseph E. Levi, Esq. via email at [email protected] or by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) demand for Krispy Kreme products declined materially at McDonald's locations after the initial marketing launch; (2) demand at McDonald's locations was a driver of declining average sales per door per week; (3) the partnership with McDonald's was not profitable; (4) the foregoing posed a substantial risk to maintaining the partnership with McDonald's; (5) as a result, the Company would pause expansion into new McDonald's locations; and (6) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
WHAT'S NEXT? If you suffered a loss in Krispy Kreme, Inc. during the relevant time frame, you have until July 15, 2025 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To learn more about this case, subscribe to the Bulls & Betrayals podcast, which features a dedicated episode unpacking the allegations against Krispy Kreme, Inc.. Listen now and find out if you are eligible to join the lawsuit.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
View the original release on www.newmediawire.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
M.Stanley takes neutral stance on Genmab ahead of portfolio, execution updates
-- Morgan Stanley has begun coverage of Genmab (CSE:GMAB) (NASDAQ:GMAB) with an Equal-Weight rating and a price objective of $24, reduced slightly from the previous $25 target. The Wall Street bank sees limited near-term upside as the most impactful catalysts are expected in 2026. 'Given that particular catalysts poised to most likely re-rate GMAB stock are anticipated to occur in 2026, we assume coverage at EW rating and look toward incremental updates on development timelines and commercial execution over the remainder of 2025,' analyst Judah C. Frommer said. Genmab is navigating a transition away from heavy reliance on Darzalex royalties and focusing more on its proprietary pipeline, particularly Epkinly, Rina-S, and acasunlimab. Following Johnson & Johnson (NYSE:JNJ)'s decision not to opt into the HexaBody-CD38 program, Frommer says attention will shift to maximizing internal pipeline value. For Epkinly, a supplemental BLA has been submitted in 2L+ follicular lymphoma based on the EPCORE-FL-1 study. While top-line data showed the study met one of its co-primary endpoints, progression-free survival data are still pending and expected later this year. More significant Phase III readouts for Epkinly in earlier-line DLBCL are scheduled for 2026. 'In the near-term however, focus remains on current commercial execution strategy in the 3L+ settings for DLBCL and FL as we await key data updates,' Frommer added. Meanwhile, Rina-S is progressing across multiple indications. At American Society of Clinical Oncology (ASCO), data in endometrial cancer showed response rates of 50% and 47% in two dose cohorts. The company plans to initiate a pivotal Phase III trial in 2L+ endometrial cancer in the second half of 2025 and a separate trial in platinum-sensitive ovarian cancer before year-end. Acasunlimab also remains a focus. Morgan Stanley expects updated Phase II data in 2L+ NSCLC later this year. The Phase III trial, which uses overall survival as the primary endpoint, is anticipated to read out in 2027. In sum, though Morgan Stanley views Genmab's management execution and pipeline-building strategy as sound, it sees 2026 as a more realistic timeframe for material stock re-rating. In the meantime, 'we look toward updates on development timelines and commercial execution over the remainder of 2025,' the bank said. Related articles takes neutral stance on Genmab ahead of portfolio, execution updates MS initiates coverage on AI Biotechs, flags key pipeline catalysts Chip stock targets raised at Mizuho following recent rally Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19 minutes ago
- Yahoo
Is First Trust RBA American Industrial Renaissance ETF (AIRR) a Strong ETF Right Now?
Making its debut on 03/10/2014, smart beta exchange traded fund First Trust RBA American Industrial Renaissance ETF (AIRR) provides investors broad exposure to the Industrials ETFs category of the market. For a long time now, the ETF industry has been flooded with products based on market capitalization weighted indexes, which are designed to represent the broader market or a particular market segment. Investors who believe in market efficiency should consider market cap indexes, as they replicate market returns in a low-cost, convenient, and transparent way. There are some investors, though, who think it's possible to beat the market with great stock selection; this group likely invests in another class of funds known as smart beta, which track non-cap weighted strategies. These indexes attempt to select stocks that have better chances of risk-return performance, based on certain fundamental characteristics or a combination of such characteristics. Even though this space provides many choices to investors--think one of the simplest methodologies like equal-weighting and more complicated ones like fundamental and volatility/momentum based weighting--not all have been able to deliver first-rate results. The fund is sponsored by First Trust Advisors. It has amassed assets over $4.01 billion, making it one of the largest ETFs in the Industrials ETFs. Before fees and expenses, this particular fund seeks to match the performance of the Richard Bernstein Advisors American Industrial Renaissance Index. The Richard Bernstein Advisors American Industrial Renaissance Index is measures the performance of small and mid cap US companies in the industrial and community banking sectors. Since cheaper funds tend to produce better results than more expensive funds, assuming all other factors remain equal, it is important for investors to pay attention to an ETF's expense ratio. Operating expenses on an annual basis are 0.70% for this ETF, which makes it one of the most expensive products in the space. It has a 12-month trailing dividend yield of 0.29%. Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund's holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis. AIRR's heaviest allocation is in the Industrials sector, which is about 90.3% of the portfolio. When you look at individual holdings, Dycom Industries, Inc. (DY) accounts for about 3.42% of the fund's total assets, followed by Bwx Technologies, Inc. (BWXT) and Emcor Group, Inc. (EME). AIRR's top 10 holdings account for about 29.7% of its total assets under management. Year-to-date, the First Trust RBA American Industrial Renaissance ETF has added roughly 8.59% so far, and is up roughly 25.16% over the last 12 months (as of 07/03/2025). AIRR has traded between $61.92 and $86.09 in this past 52-week period. AIRR has a beta of 1.27 and standard deviation of 25.10% for the trailing three-year period, which makes the fund a high risk choice in the space. With about 57 holdings, it effectively diversifies company-specific risk . First Trust RBA American Industrial Renaissance ETF is an excellent option for investors seeking to outperform the Industrials ETFs segment of the market. There are other ETFs in the space which investors could consider as well. Vanguard Industrials ETF (VIS) tracks MSCI US Investable Market Industrials 25/50 Index and the Industrial Select Sector SPDR ETF (XLI) tracks Industrial Select Sector Index. Vanguard Industrials ETF has $5.73 billion in assets, Industrial Select Sector SPDR ETF has $22.03 billion. VIS has an expense ratio of 0.09% and XLI changes 0.08%. Investors looking for cheaper and lower-risk options should consider traditional market cap weighted ETFs that aim to match the returns of the Industrials ETFs To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report First Trust RBA American Industrial Renaissance ETF (AIRR): ETF Research Reports This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
38 minutes ago
- Yahoo
The McDonald's Boycott Every Investor Needs to Know About
President Donald Trump rode various waves of sentiment to return him to the Oval Office. One of the key areas of contention that got him re-elected was his attack on diversity, equity and inclusion (DEI) initiatives. Soon after his return, Trump swiftly acted to undo many DEI programs in federal agencies. Many companies followed suit, rolling back or eliminating their respective programs. Discover More: Read Next: Consumer sentiment has been balanced, but those upset by actions taken by corporate America have made themselves heard by imposing economic blackouts on firms. McDonald's is the latest company drawing the ire of upset Americans and their stock prices are reflecting that. Here's what investors should know. McDonald's was one of the first companies to roll back its DEI initiatives. 'We are retiring setting aspirational representation goals and instead keeping our focus on continuing to embed inclusion practices that grow our business into our everyday process and operations,' said McDonald's in a letter to its restaurant owners and operators in early January. The company announced numerous other changes to its DEI programs in the letter. Those moves didn't go unnoticed by The People's Union, a grassroots group that supports DEI and corporate responsibility. The group called for a boycott of McDonald's from June 24 to 30. Besides pausing DEI initiatives, the boycott of McDonald's was due to its perceived price gouging, use of tax loopholes, exploitation of workers, corporate greed and political corruption, according to a recent Instagram post. It's arguable whether or not economic blackouts work. However, the boycott of McDonald's couldn't come at a worse time for the company. The fast food chain saw U.S. sales decrease by 3.6% in the first quarter of 2025, making it the worst quarter since the second quarter of 2020. McDonald's serves 26 million customers in the United States daily. That's enough volume to withstand some slumps but given that it has seen same-store sales fall for two consecutive quarters, following it up with another quarter of losses won't look good. McDonald's isn't the only corporation to face economic blackouts. Firms that have faced similar backlashes include Amazon, Target and Walmart. Some faced a one-day boycott on February 28, whereas others faced extended boycotts. Amazon, for one, actually saw an increase in sales on its one-day boycott, according to Newsweek. Similarly, Costco experienced an impressive 22% increase in web traffic on February 28, thanks to its commitment to keeping DEI initiatives. Walmart saw a slight decrease, but Target fared significantly worse. The company faced a 40-day boycott due to rolling back DEI initiatives, and the retailer conceded sales were impacted by the action, according to CNN. Net sales decreased by 2.8% in the first quarter of 2025 versus the same period in 2024. It's debatable whether boycotts work, but the repercussions can vary widely. It won't be clear how McDonald's boycott led by The People's Union will impact sales until it reports its next earnings. Given how the restaurant has fared in recent quarters, investors may need to brace for further lagging sales. More From GOBankingRates 10 Unreliable SUVs To Stay Away From Buying This article originally appeared on The McDonald's Boycott Every Investor Needs to Know About
